APGE
NASDAQ · Biotechnology
Apogee Therapeutics Inc
$135.07
-0.01 (-0.01%)
APGE News11 articles
AbbVie Completes $10.9B Apogee Buyout, Earnings Lift Delayed to 2032
AbbVie finalizes its $10.9B Apogee Therapeutics deal, with earnings accretion not expected until 2032. The acquisition tests investor patience as immunology sales fuel the wait.
AbbVie Completes $10.9B Apogee Buyout, Accretion Delayed to 2032
AbbVie closes its $10.9B Apogee acquisition, projecting EPS dilution until 2032, while strong Skyrizi and Rinvoq growth funds the long-term bet.
AbbVie Surges $17.8 Billion in Market Cap, Surpassing Apogee Deal Value
AbbVie shares soared 3.99% to $261.07, adding $17.8B in market value—more than the $10.9B Apogee deal. The stock now trades above analyst targets, setting up a key Q2 earnings report.
AbbVie's $65B Surge Outpaces Apogee Acquisition Cost by Sixfold
AbbVie's stock surge added $65B in market cap, six times its $10.9B Apogee deal cost, as Skyrizi approval and immunology demand offset Humira declines.
AbbVie surges $18B in value ahead of Skyrizi pediatric approval
AbbVie shares soared 4.2% to a 52-week high, adding $18 billion in market value, surpassing the $10.9 billion Apogee acquisition price. FDA approval for pediatric Skyrizi use came after the close.
Alphabet's AI Cost Fears Trigger Nasdaq Slide; Dow Gains on Oil Drop
Alphabet (GOOGL) tumbled 5.5% on AI spending worries, pulling the Nasdaq down 1.41%, while a drop in oil prices lifted the Dow 0.12%.
AbbVie Acquires Apogee Therapeutics for $10.9B in Cash, Bolstering Pipeline
AbbVie announced a $10.9 billion cash acquisition of Apogee Therapeutics, adding a promising eczema treatment to its pipeline as it seeks to offset declining Humira sales.
S&P 500 Edges Up, Nasdaq Slips as Micron Surge Offsets Tech Weakness
The S&P 500 and Dow edged higher, but the Nasdaq slipped as Micron's nearly 5% gain lifted chip stocks, while rising yields weighed on mega-cap tech.
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash
Apogee Therapeutics stock jumped 47% after AbbVie agreed to buy the company for $135.11 per share in cash, adding late-stage eczema drug zumilokibart.
AbbVie to Buy Apogee in $10.9B Deal to Boost Immunology Pipeline
AbbVie acquires Apogee Therapeutics for $10.9 billion, paying a 49.49% premium for experimental eczema drug zumilokibart, as it seeks to bolster its immunology franchise.
AbbVie Nears $10.9B Apogee Takeover, Healthcare Stocks in Focus
AbbVie is reportedly close to acquiring Apogee Therapeutics for $10.9 billion in cash, offering a roughly 60% premium. A deal could be announced Monday, putting healthcare stocks in the spotlight.